1. Home
  2. IMRN

as of 11-19-2026 3:55pm EST

$0.88
+$0.03
+3.40%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Founded: 1994 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 7.7M IPO Year: 2016
Target Price: N/A AVG Volume (30 days): 13.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.68 - $1.99 Next Earning Date: 08-28-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 12% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered IMRN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

sell
Model Precision: 9.09%
9.09%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: